Home Featured Page 226

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Mouse Study Reveals New Details on Psilocybin’s Rewiring of the Brain

Is Nitrous Oxide a Psychedelic Drug?

Keeping Participants Safe in Psychedelic Research

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD...

atai Launches Revixia Life Sciences to Develop Salvinorin A for a...

Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under...

Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin...

Cybin Announces Additional Adelia Milestone Achievements

Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple...

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at...

1...225226227...296 Page 226 of 296

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Mouse Study Reveals New Details on Psilocybin’s Rewiring of the Brain

Is Nitrous Oxide a Psychedelic Drug?

Keeping Participants Safe in Psychedelic Research

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD...

atai Launches Revixia Life Sciences to Develop Salvinorin A for a...

Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under...

Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin...

Cybin Announces Additional Adelia Milestone Achievements

Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple...

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at...

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY